114 related articles for article (PubMed ID: 38900252)
1. Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus.
Talebi SS; Rezaie S; Hajmiri MS; Zamanirafe M; Ranjbar A; Moridi H; Mirjalili M; Mehrpooya M
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38900252
[TBL] [Abstract][Full Text] [Related]
2. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Kutoh E; Wada A; Hayashi J
Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
[TBL] [Abstract][Full Text] [Related]
3. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial.
Zakaraia HG; Salem HF; Mostafa MAA; Ali AM; Rabea H
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):7289-7298. PubMed ID: 37606137
[TBL] [Abstract][Full Text] [Related]
4. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of asprosin in new-onset type 2 diabetes.
Naiemian S; Naeemipour M; Zarei M; Lari Najafi M; Gohari A; Behroozikhah MR; Heydari H; Miri M
Diabetol Metab Syndr; 2020; 12():65. PubMed ID: 32714446
[TBL] [Abstract][Full Text] [Related]
6. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
Khaloo P; Asadi Komeleh S; Alemi H; Mansournia MA; Mohammadi A; Yadegar A; Afarideh M; Esteghamati S; Nakhjavani M; Esteghamati A
J Endocrinol Invest; 2019 Jul; 42(7):851-857. PubMed ID: 30535871
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
Derosa G; Ragonesi PD; Fogari E; Cicero AF; Bianchi L; Bonaventura A; Romano D; Maffioli P
Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC
Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
[TBL] [Abstract][Full Text] [Related]
10. Effect of Sitagliptin
Hematyar J; Rashidi H; Zakerkish M; Payami SP; Ghaderian SB
Maedica (Bucur); 2022 Dec; 17(4):762-770. PubMed ID: 36818268
[No Abstract] [Full Text] [Related]
11. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
[TBL] [Abstract][Full Text] [Related]
12. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation.
Ahmed M; Saeed A; Khan MZ; Javaid SZ; Aslam F; Dar SI
Cureus; 2023 Sep; 15(9):e44709. PubMed ID: 37809225
[TBL] [Abstract][Full Text] [Related]
14. Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
Dai C; Zhu W
Medicine (Baltimore); 2022 Oct; 101(43):e31334. PubMed ID: 36316938
[TBL] [Abstract][Full Text] [Related]
15. Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.
Ji M; Xia L; Cao J; Zou D
Medicine (Baltimore); 2016 Mar; 95(11):e2961. PubMed ID: 26986104
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
18. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
19. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Derosa G; Carbone A; Franzetti I; Querci F; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
[TBL] [Abstract][Full Text] [Related]
20. Comparative Study on Efficacy of Empagliflozin Versus Sitagliptin, as an Add-on Therapy to Metformin in Type 2 Diabetic Patients.
Salankar H; Rode S; Arjun C; Joseph R; Deshmane GB; Vijayan RP
J Pharm Bioallied Sci; 2024 Feb; 16(Suppl 1):S335-S338. PubMed ID: 38595418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
